Regeneron Pharmaceuticals reports revenue growth amid institutional investment shifts

Regeneron Pharmaceuticals has seen significant activity regarding its stock performance and institutional ownership. While the company's shares have declined from all-time highs to levels slightly below $800, recent second-quarter financial results showed a 17% year-over-year revenue increase to $4.3 billion.

Growth has been largely driven by Dupixent, a medicine co-marketed with Sanofi, which saw global net sales rise 38% to $6 billion. To defend against future patent expirations, the company is developing a higher-dose formulation of Dupixent. Regeneron has also utilized high-dose formulations to mitigate competition for its Eylea products, where Eylea HD sales rose 52% year-over-year.

In terms of institutional investment, State Street Corp increased its holdings in Regeneron by 3.6% during the second quarter, owning over 4.8 million shares. Other major investors, including BlackRock Inc., have also established or increased positions in the company. Currently, institutional investors own approximately 83.31% of Regeneron's stock.